The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...
Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
Blue Shield of California is bypassing traditional pharmacy benefit managers to offer a Humira (adalimumab)-referenced biosimilar named Idacio to patients at the lowest list price currently ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results